Parallel Bio combines a scalable human immune organoid with AI to generate population-scale human biological data for drug discovery, reporting 87% concordance with clinical data.
Parallel Bio is a drug discovery company built around a single technological claim: that human biology, not animal models, should be the basis of preclinical research. Its platform combines the world's first scalable human immune organoid with artificial intelligence to generate population-scale, fully human biological data. The organoid replicates the human immune system in vitro, allowing the company to model immune responses across a range of human backgrounds rather than in surrogate species.
The technology has produced measurable results. Its readouts show 87% concordance with clinical patient data, against 3% for traditional animal models. More than 50 compounds have been tested across 170+ unique patient backgrounds. The gap it addresses is well documented: more than 95% of drugs that succeed in animal models go on to fail in humans.
The work spans several technical domains, including human immune organoid technology, immunology, in vitro human biology modelling, and machine learning applied to biological data generation. Applications sit within pharmaceuticals, immunotherapy and preclinical research. The company partners with Fortune 500 pharmaceutical firms and states an explicit goal of removing animal testing from the drug development pipeline while reducing its time and cost.
Further detail is available at https://parallel.bio/.
